ACRV - CIK 0001781174
The table below shows Acrivon Therapeutics, Inc.'s cash flow statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$63.66M | -$65.67M | -$42.64M | -$30.12M | -$13.98M |
| Capital expenditure | $1.67M | $2.77M | $1.29M | $2.17M | $238.00K |
| Investing cash flow | $66.10M | -$51.77M | $50.72M | -$141.68M | -$238.00K |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - | - | - |
Acrivon Therapeutics, Inc. reported operating cash flow of -$63.66M for fiscal year 2025. That is up 3.1% from -$65.67M in fiscal 2024. Over the 5 fiscal years shown, operating cash flow declined from -$13.98M (FY 2021) to -$63.66M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Financing cash flow | -$749.00K | $121.03M | -$1.55M | $101.71M | $112.22M |